The DOI matches its Crossref record; 214 of the 214 references it cites were found in a registry or an index.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)
Open accessAbstract
BACKGROUND The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS To review, from an Infectious Diseases perspective, the safety profile of agents targeting interleukins, immunoglobulins and complement factors and to suggest preventive recommendations. SOURCES Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family. CONTENT Patients receiving interleukin-1 (IL-1) -targeted (anakinra, canakinumab or rilonacept) or IL-5-targeted (mepolizumab) agents have a moderate risk of infection and no specific prevention strategies are recommended. The use of IL-6/IL-6 receptor-targeted agents (tocilizumab and siltuximab) is associated with a risk increase similar to that observed with anti-tumour necrosis factor-α agents. IL-12/23-targeted agents (ustekinumab) do not seem to pose a meaningful risk of infection, although screening for latent tuberculosis infection may be considered and antiviral prophylaxis should be given to hepatitis B surface antigen-positive patients. Therapy with IL-17-targeted agents (secukinumab, brodalumab and ixekizumab) may result in the development of mild-to-moderate mucocutaneous candidiasis. Pre-treatment screening for Strongyloides stercoralis and other geohelminths should be considered in patients who come from areas where these are endemic who are receiving IgE-targeted agents (omalizumab). C5-targeted agents (eculizumab) are associated with a markedly increased risk of infection due to encapsulated bacteria, particularly Neisseria spp. Meningococcal vaccination and chemoprophylaxis must be administered 2-4 weeks before initiating eculizumab. Patients with high-risk behaviours and their partners should also be screened for gonococcal infection. IMPLICATIONS Preventive strategies are particularly encouraged to minimize the occurrence of neisserial infection associated with eculizumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene
Poltorak, A., He, X., Smirnova, I., Liu, M.-Y., Huffel, C. V., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., et al. (1998) · Science · doi:10.1126/science.282.5396.2085 · Cited by 7,631
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511 · cited 1×
“Expected impact on the infection risk Critical to the understanding of the mode of action of tocilizumab and other IL-6- or IL-6Rtargeted agents is the recognition that this pleiotropic cytokine has a characteristic signaling pathway, also shared by other members of the so-called IL-6-type or gp130 group of cytokines…”
BackgroundMepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,871
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
(2013) · Pediatrics · doi:10.1542/peds.2013-2511 · Cited by 1,845
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Feagan, B. G., Sandborn, W. J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J. R., Blank, M. A., Johanns, J., Gao, L.-L., Miao, Y., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602773 · Cited by 1,845
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Bel, E. H., Wenzel, S. E., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S. W., Ortega, H. G., & Pavord, I. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403291 · Cited by 1,661
Man, S. M., Karki, R., & Kanneganti, T. (2017) · Immunological Reviews · doi:10.1111/imr.12534 · Cited by 1,657
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
Rubin, L. G., Levin, M. J., Ljungman, P., Davies, E. G., Avery, R., Tomblyn, M., Bousvaros, A., Dhanireddy, S., Sung, L., Keyserling, H., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit684 · Cited by 1,613
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Trial of tocilizumab in giant-cell arteritis
Stone, J. H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613849 · Cited by 1,386
Busse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., van As, A., & Gupta, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117880 · Cited by 1,307
Castro, M., Zangrilli, J., Wechsler, M. E., Bateman, E. D., Brusselle, G. G., Bardin, P., Murphy, K., Maspero, J. F., O'Brien, C., & Korn, S. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00042-9 · Cited by 1,182
Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J., Beeh, K. ‐., Ramos, S., Canonica, G. W., Hedgecock, S., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00772.x · Cited by 1,123
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Wechsler, M. E., Akuthota, P., Jayne, D., Khoury, P., Klion, A., Langford, C. A., Merkel, P. A., Moosig, F., Specks, U., Cid, M. C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702079 · Cited by 1,094
CD56bright natural killer (NK) cells: an important NK cell subset
Poli, A., Michel, T., Thérésine, M., Andrès, E., Hentges, F., & Zimmer, J. (2009) · Immunology · doi:10.1111/j.1365-2567.2008.03027.x · Cited by 977
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
The IL-12 Family of Heterodimeric Cytokines
Trinchieri, G., Pflanz, S., & Kastelein, R. A. (2003) · Immunity · doi:10.1016/s1074-7613(03)00296-6 · Cited by 922
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009705 · Cited by 884
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503824 · Cited by 828
MacGlashan, D. W., Bochner, B. S., Adelman, D. C., Jardieu, P. M., Togias, A., McKenzie-White, J., Sterbinsky, S. A., Hamilton, R. G., & Lichtenstein, L. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1438 · Cited by 823
McInnes, I. B., Kavanaugh, A., Gottlieb, A. B., Puig, L., Rahman, P., Ritchlin, C., Brodmerkel, C., Li, S., Wang, Y., Mendelsohn, A. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60594-2 · Cited by 807
Protective immune mechanisms in helminth infection
Anthony, R. M., Rutitzky, L. I., Urban, J. F., Stadecker, M. J., & Gause, W. C. (2007) · Nature Reviews Immunology · doi:10.1038/nri2199 · Cited by 779
IL‐12 and IL‐23: master regulators of innate and adaptive immunity
Langrish, C. L., McKenzie, B. S., Wilson, N. J., De Waal Malefyt, R., Kastelein, R. A., & Cua, D. J. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00214.x · Cited by 753
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Mease, P. J., McInnes, I. B., Kirkham, B., Kavanaugh, A., Rahman, P., van der Heijde, D., Landewé, R., Nash, P., Pricop, L., Yuan, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412679 · Cited by 746
A pilot study of IL-1 inhibition by anakinra in acute gout
So, A., De Smedt, T., Revaz, S., & Tschopp, J. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2143 · Cited by 727
Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Ruperto, N., Brunner, H. I., Quartier, P., Constantin, T., Wulffraat, N., Horneff, G., Brik, R., McCann, L., Kasapcopur, O., Rutkowska-Sak, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205099 · Cited by 713
Bustamante, J., Boisson-Dupuis, S., Abel, L., & Casanova, J.-L. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.09.008 · Cited by 684
Ritchlin, C., Rahman, P., Kavanaugh, A., McInnes, I. B., Puig, L., Li, S., Wang, Y., Shen, Y.-K., Doyle, M. K., Mendelsohn, A. M., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204655 · Cited by 662
Brodsky, R. A., Young, N. S., Antonioli, E., Risitano, A. M., Schrezenmeier, H., Schubert, J., Gaya, A., Coyle, L., de Castro, C., Fu, C.-L., et al. (2008) · Blood · doi:10.1182/blood-2007-06-094136 · Cited by 652
Cohen, S., Hurd, E., Cush, J., Schiff, M., Weinblatt, M. E., Moreland, L. W., Kremer, J., Bear, M. B., Rich, W. J., & McCabe, D. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10141 · Cited by 638
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease
Pavord, I. D., Chanez, P., Criner, G. J., Kerstjens, H. A. M., Korn, S., Lugogo, N., Martinot, J.-B., Sagara, H., Albers, F. C., Bradford, E. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708208 · Cited by 625
Baeten, D., Baraliakos, X., Braun, J., Sieper, J., Emery, P., van der Heijde, D., McInnes, I., van Laar, J. M., Landewé, R., Wordsworth, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61134-4 · Cited by 595
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
Rothenberg, M. E., Klion, A. D., Roufosse, F. E., Kahn, J. E., Weller, P. F., Simon, H.-U., Schwartz, L. B., Rosenwasser, L. J., Ring, J., Griffin, E. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa070812 · Cited by 583
Hillmen, P., Muus, P., Dührsen, U., Risitano, A. M., Schubert, J., Luzzatto, L., Schrezenmeier, H., Szer, J., Brodsky, R. A., Hill, A., et al. (2007) · Blood · doi:10.1182/blood-2007-06-095646 · Cited by 579
Stegall, M. D., Diwan, T., Raghavaiah, S., Cornell, L. D., Burns, J., Dean, P. G., Cosio, F. G., Gandhi, M. J., Kremers, W., & Gloor, J. M. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03757.x · Cited by 577
Kaplan, A., Ledford, D., Ashby, M., Canvin, J., Zazzali, J. L., Conner, E., Veith, J., Kamath, N., Staubach, P., Jakob, T., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.05.013 · Cited by 573
Treating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
Genovese, M. C., Cohen, S., Moreland, L., Lium, D., Robbins, S., Newmark, R., Bekker, P., & for the 20000223 Study Group (2004) · Arthritis & Rheumatism · doi:10.1002/art.20221 · Cited by 532
Kelly, R. J., Hill, A., Arnold, L. M., Brooksbank, G. L., Richards, S. J., Cullen, M., Mitchell, L. D., Cohen, D. R., Gregory, W. M., & Hillmen, P. (2011) · Blood · doi:10.1182/blood-2011-02-333997 · Cited by 526
Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial
Bachert, C., Sousa, A. R., Lund, V. J., Scadding, G. K., Gevaert, P., Nasser, S., Durham, S. R., Cornet, M. E., Kariyawasam, H. H., Gilbert, J., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.05.044 · Cited by 505
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
on behalf of the French Study Group for aHUS/C3G, Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C., & Frémeaux-Bacchi, V. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.214 · Cited by 496
van Rhee, F., Wong, R. S., Munshi, N., Rossi, J.-F., Ke, X.-Y., Fosså, A., Simpson, D., Capra, M., Liu, T., Hsieh, R. K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70319-5 · Cited by 454
The IL-23-IL-17 axis in inflammatory arthritis
Lubberts, E. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.53 · Cited by 442
Interleukin‐4‐ and interleukin‐13‐mediated host protection against intestinal nematode parasites
Finkelman, F. D., Shea‐Donohue, T., Morris, S. C., Gildea, L., Strait, R., Madden, K. B., Schopf, L., & Urban, J. F. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00192.x · Cited by 440
Assa'ad, A. H., Gupta, S. K., Collins, M. H., Thomson, M., Heath, A. T., Smith, D. A., Perschy, T. L., Jurgensen, C. H., Ortega, H. G., & Aceves, S. S. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.044 · Cited by 435
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
Bjermer, L., Lemiere, C., Maspero, J., Weiss, S., Zangrilli, J., & Germinaro, M. (2016) · Chest · doi:10.1016/j.chest.2016.03.032 · Cited by 426
The role of IL-6 in host defence against infections: immunobiology and clinical implications
Rose-John, S., Winthrop, K., & Calabrese, L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.83 · Cited by 424
Self-citationEculizumab in Severe Shiga-Toxin–Associated HUS
Lapeyraque, A.-L., Malina, M., Fremeaux-Bacchi, V., Boppel, T., Kirschfink, M., Oualha, M., Proulx, F., Clermont, M.-J., Le Deist, F., Niaudet, P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1100859 · Cited by 423
Licht, C., Greenbaum, L. A., Muus, P., Babu, S., Bedrosian, C. L., Cohen, D. J., Delmas, Y., Douglas, K., Furman, R. R., Gaber, O. A., et al. (2015) · Kidney International · doi:10.1038/ki.2014.423 · Cited by 420
Lequerré, T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., Kone-Paut, I., Michel, M., Dernis, E., Khellaf, M., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.076034 · Cited by 406
Vignola, A. M., Humbert, M., Bousquet, J., Boulet, L., Hedgecock, S., Blogg, M., Fox, H., & Surrey, K. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00550.x · Cited by 405
Brucato, A., Imazio, M., Gattorno, M., Lazaros, G., Maestroni, S., Carraro, M., Finetti, M., Cumetti, D., Carobbio, A., Ruperto, N., et al. (2016) · JAMA · doi:10.1001/jama.2016.15826 · Cited by 401
Pittock, S. J., Lennon, V. A., McKeon, A., Mandrekar, J., Weinshenker, B. G., Lucchinetti, C. F., O'Toole, O., & Wingerchuk, D. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70076-0 · Cited by 395
Revisiting Human IL-12Rβ1 Deficiency: A Survey of 141 Patients From 30 Countries
de Beaucoudrey, L., Samarina, A., Bustamante, J., Cobat, A., Boisson-Dupuis, S., Feinberg, J., Al-Muhsen, S., Jannière, L., Rose, Y., de Suremain, M., et al. (2010) · Medicine · doi:10.1097/md.0b013e3181fdd832 · Cited by 394
Fleischmann, R. M., Schechtman, J., Bennett, R., Handel, M. L., Burmester, G., Tesser, J., Modafferi, D., Poulakos, J., & Sun, G. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10870 · Cited by 392
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma
Corren, J., Weinstein, S., Janka, L., Zangrilli, J., & Garin, M. (2016) · Chest · doi:10.1016/j.chest.2016.03.018 · Cited by 388
Casale, T. B. (2001) · JAMA · doi:10.1001/jama.286.23.2956 · Cited by 377
Kalb, R. E., Fiorentino, D. F., Lebwohl, M. G., Toole, J., Poulin, Y., Cohen, A. D., Goyal, K., Fakharzadeh, S., Calabro, S., Chevrier, M., et al. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.0718 · Cited by 373
Integrated safety in tocilizumab clinical trials
Schiff, M. H., Kremer, J. M., Jahreis, A., Vernon, E., Isaacs, J. D., & van Vollenhoven, R. F. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3455 · Cited by 367
Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis
Bomback, A. S., Smith, R. J., Barile, G. R., Zhang, Y., Heher, E. C., Herlitz, L., Stokes, M. B., Markowitz, G. S., D’Agati, V. D., Canetta, P. A., et al. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12901211 · Cited by 366
Schlesinger, N., Alten, R. E., Bardin, T., Schumacher, H. R., Bloch, M., Gimona, A., Krammer, G., Murphy, V., Richard, D., & So, A. K. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200908 · Cited by 359
Kuehr, J., Brauburger, J., Zielen, S., Schauer, U., Kamin, W., Von Berg, A., Leupold, W., Bergmann, K.-C., Rolinck-Werninghaus, C., Gräve, M., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.121949 · Cited by 342
Oldhoff, J. M., Darsow, U., Werfel, T., Katzer, K., Wulf, A., Laifaoui, J., Hijnen, D. J., Plötz, S., Knol, E. F., Kapp, A., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00791.x · Cited by 339
IL-6 biology: implications for clinical targeting in rheumatic disease
Calabrese, L. H., & Rose-John, S. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.127 · Cited by 328
Self-citationInborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis
Puel, A., Cypowyj, S., Maródi, L., Abel, L., Picard, C., & Casanova, J.-L. (2012) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0b013e328358cc0b · Cited by 315
So, A., De Meulemeester, M., Pikhlak, A., Yücel, A. E., Richard, D., Murphy, V., Arulmani, U., Sallstig, P., & Schlesinger, N. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27600 · Cited by 315
Blauvelt, A., Reich, K., Tsai, T.-F., Tyring, S., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Vender, R., Hugot, S., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.08.008 · Cited by 312
Kim, D. K., Riley, L. E., Harriman, K. H., Hunter, P., & Bridges, C. B. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6605e2 · Cited by 309
Safety of extended treatment with anakinra in patients with rheumatoid arthritis
Fleischmann, R. M., Tesser, J., Schiff, M. H., Schechtman, J., Burmester, G.-R., Bennett, R., Modafferi, D., Zhou, L., Bell, D., & Appleton, B. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.048371 · Cited by 305
van de Kerkhof, P. C. M., Griffiths, C. E. M., Reich, K., Leonardi, C. L., Blauvelt, A., Tsai, T.-F., Gong, Y., Huang, J., Papavassilis, C., & Fox, T. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.03.024 · Cited by 302
Yehoshua, Z., Alexandre de Amorim Garcia Filho, C., Nunes, R. P., Gregori, G., Penha, F. M., Moshfeghi, A. A., Zhang, K., Sadda, S., Feuer, W., & Rosenfeld, P. J. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.044 · Cited by 299
Molecules Great and Small: The Complement System
Mathern, D. R., & Heeger, P. S. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06230614 · Cited by 290
Recent advances in the IL-17 cytokine family
Gaffen, S. L. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.07.006 · Cited by 283
Lugogo, N., Domingo, C., Chanez, P., Leigh, R., Gilson, M. J., Price, R. G., Yancey, S. W., & Ortega, H. G. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.07.010 · Cited by 283
Ayres, J. G., Higgins, B., Chilvers, E. R., Ayre, G., Blogg, M., & Fox, H. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00533.x · Cited by 279
Burmester, G. R., Lin, Y., Patel, R., van Adelsberg, J., Mangan, E. K., Graham, N. M. H., van Hoogstraten, H., Bauer, D., Ignacio Vargas, J., & Lee, E. B. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210310 · Cited by 272
Saunte, D. M., Mrowietz, U., Puig, L., & Zachariae, C. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15015 · Cited by 270
Neven, B., Marvillet, I., Terrada, C., Ferster, A., Boddaert, N., Couloignier, V., Pinto, G., Pagnier, A., Bodemer, C., Bodaghi, B., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.25057 · Cited by 265
Production and Activities of IgE in Helminth Infection
Jarrett, E. E. E., & Miller, H. R. P. (2015) · Chemical Immunology and Allergy · doi:10.1159/000406534 · Cited by 263
Complement and viral pathogenesis
Stoermer, K. A., & Morrison, T. E. (2011) · Virology · doi:10.1016/j.virol.2010.12.045 · Cited by 255
Schlesinger, N., Mysler, E., Lin, H.-Y., De Meulemeester, M., Rovensky, J., Arulmani, U., Balfour, A., Krammer, G., Sallstig, P., & So, A. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.144063 · Cited by 244
Howard, J. F., Barohn, R. J., Cutter, G. R., Freimer, M., Juel, V. C., Mozaffar, T., Mellion, M. L., Benatar, M. G., Farrugia, M. E., Wang, J. J., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.23839 · Cited by 225
Strand, V., Ahadieh, S., French, J., Geier, J., Krishnaswami, S., Menon, S., Checchio, T., Tensfeldt, T. G., Hoffman, E., Riese, R., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0880-2 · Cited by 223
Nuki, G., Bresnihan, B., Bear, M. B., & McCabe, D. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10578 · Cited by 222
Sibley, C. H., Plass, N., Snow, J., Wiggs, E. A., Brewer, C. C., King, K. A., Zalewski, C., Kim, H. J., Bishop, R., Hill, S., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34409 · Cited by 220
Genovese, M. C., Fleischmann, R., Kivitz, A. J., Rell‐Bakalarska, M., Martincova, R., Fiore, S., Rohane, P., van Hoogstraten, H., Garg, A., Fan, C., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39093 · Cited by 219
Chervinsky, P., Casale, T., Townley, R., Tripathy, I., Hedgecock, S., Fowler-Taylor, A., Shen, H., & Fox, H. (2003) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)62171-0 · Cited by 215
Tsai, T.-F., Ho, J.-C., Song, M., Szapary, P., Guzzo, C., Shen, Y.-K., Li, S., Kim, K.-J., Kim, T.-Y., Choi, J.-H., et al. (2011) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2011.05.005 · Cited by 212
Koike, T., Harigai, M., Inokuma, S., Ishiguro, N., Ryu, J., Takeuchi, T., Takei, S., Tanaka, Y., Sano, Y., Yaguramaki, H., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130466 · Cited by 208
Folaranmi, T. A., Rubin, L. G., Martin, S. W., Patel, M., & MacNeil, J. R. (2015) · PubMed Central · Cited by 202
Positive Crossmatch Kidney Transplant Recipients Treated With Eculizumab: Outcomes Beyond 1 Year
Cornell, L. D., Schinstock, C. A., Gandhi, M. J., Kremers, W. K., & Stegall, M. D. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13168 · Cited by 199
Blok, J. L., Li, K., Brodmerkel, C., Horvátovich, P., Jonkman, M. F., & Horváth, B. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14338 · Cited by 193
Response of host inflammasomes to viral infection
Chen, I.-Y., & Ichinohe, T. (2015) · Trends in Microbiology · doi:10.1016/j.tim.2014.09.007 · Cited by 189
Clinical Efficacy and Immunologic Effects of Omalizumab in Allergic Bronchopulmonary Aspergillosis
Voskamp, A. L., Gillman, A., Symons, K., Sandrini, A., Rolland, J. M., O'Hehir, R. E., & Douglass, J. A. (2015) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2014.12.008 · Cited by 185
Omalizumab is effective in the long-term control of severe allergic asthma
Lanier, B. Q., Corren, J., Lumry, W., Liu, J., Fowler-Taylor, A., & Gupta, N. (2003) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)62170-9 · Cited by 183
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Buhl, R., Solèr, M., Matz, J., Townley, R., O'Brien, J., Noga, O., Champain, K., Fox, H., Thirlwell, J., & Della Cioppa, G. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00278102 · Cited by 179
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes
Roufosse, F. E., Kahn, J.-E., Gleich, G. J., Schwartz, L. B., Singh, A. D., Rosenwasser, L. J., Denburg, J. A., Ring, J., Rothenberg, M. E., Sheikh, J., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.055 · Cited by 178
Kuemmerle-Deschner, J. B., Tyrrell, P. N., Koetter, I., Wittkowski, H., Bialkowski, A., Tzaribachev, N., Lohse, P., Koitchev, A., Deuter, C., Foell, D., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30149 · Cited by 177
Varricchi, G., Bagnasco, D., Borriello, F., Heffler, E., & Canonica, G. W. (2016) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0000000000000251 · Cited by 177
Noga, O., Hanf, G., Brachmann, I., Klucken, A. C., Kleine-Tebbe, J., Rosseau, S., Kunkel, G., Suttorp, N., & Seybold, J. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.02.028 · Cited by 170
Peffault de Latour, R., Fremeaux-Bacchi, V., Porcher, R., Xhaard, A., Rosain, J., Castaneda, D. C., Vieira-Martins, P., Roncelin, S., Rodriguez-Otero, P., Plessier, A., et al. (2015) · Blood · doi:10.1182/blood-2014-03-560540 · Cited by 168
Clinical Significance of Complement Deficiencies
Pettigrew, H. D., Teuber, S. S., & Gershwin, M. E. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04633.x · Cited by 164
PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and Treatment
Cugno, M., Borghi, A., & Marzano, A. V. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0265-1 · Cited by 162
Xie, F., Yun, H., Bernatsky, S., & Curtis, J. R. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39761 · Cited by 161
The Ying and Yang of STAT3 in Human Disease
Vogel, T. P., Milner, J. D., & Cooper, M. A. (2015) · Journal of Clinical Immunology · doi:10.1007/s10875-015-0187-8 · Cited by 159
Mease, P. J., Gottlieb, A. B., Berman, A., Drescher, E., Xing, J. W., Wong, R. L., & Banerjee, S. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39700 · Cited by 152
Psoriasis: rationale for targeting interleukin-17
Girolomoni, G., Mrowietz, U., & Paul, C. F. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.11099.x · Cited by 151
Stein, M., Villanueva, J. M., Buckmeier, B. K., Yamada, Y., Filipovich, A. H., Assa’ad, A., & Rothenberg, M. E. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.02.033 · Cited by 148
Hossain, M. M., & Norazmi, M. N. (2013) · BioMed Research International · doi:10.1155/2013/179174 · Cited by 147
Chiu, H., Chen, C., Wu, M., Cheng, Y. ‐., & Tsai, T. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12461 · Cited by 144
Gordon, K. B., Papp, K. A., Langley, R. G. B., HO, V. C., Kimball, A. B., Guzzo, C. A., Yeilding, N. M., Szapary, P. O., Fakharzadeh, S. S., Li, S., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.06.041 · Cited by 142
Evaluation and Differential Diagnosis of Marked, Persistent Eosinophilia
Nutman, T. B. (2007) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2007.07.008 · Cited by 142
Jodele, S., Fukuda, T., Mizuno, K., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.10.002 · Cited by 140
Bellamy, R., Ruwende, C., Corrah, T., Mcadam, K. P. W. J., Whittle, H., & Hill, A. V. S. (1998) · Tubercle and Lung Disease · doi:10.1054/tuld.1998.0009 · Cited by 140
Smolen, J. S., Weinblatt, M. E., Sheng, S., Zhuang, Y., & Hsu, B. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205137 · Cited by 139
Self-citationBrodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
Farahnik, B., Beroukhim, K., Abrouk, M. E., Nakamura, M., Zhu, T. H., Singh, R., Lee, K. M., Bhutani, T., & Koo, J. Y. M. (2016) · Dermatology and Therapy · doi:10.1007/s13555-016-0121-x · Cited by 138
Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes
Kullenberg, T., Löfqvist, M., Leinonen, M., Goldbach‐Mansky, R. T., & Olivecrona, H. (2016) · Rheumatology · doi:10.1093/rheumatology/kew208 · Cited by 138
Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review
Devalet, B., Mullier, F., Châtelain, B., Dogné, J., & Chatelain, C. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12543 · Cited by 134
Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis
Wang, H.-H., Li, Y., & Huang, Y. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.05.038 · Cited by 134
Genovese, M. C., Fleischmann, R., Furst, D., Janssen, N., Carter, J., Dasgupta, B., Bryson, J., Duncan, B., Zhu, W., Pitzalis, C., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204760 · Cited by 132
Safety of secukinumab in the treatment of psoriasis
Blauvelt, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1221923 · Cited by 130
Terkeltaub, R. A., Schumacher, H. R., Carter, J. D., Baraf, H. S. B., Evans, R. R., Wang, J., King-Davis, S., & Weinstein, S. P. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4159 · Cited by 122
Meningococcal Sepsis Complicating Eculizumab Treatment Despite Prior Vaccination
Struijk, G. H., Bouts, A. H. M., Rijkers, G. T., Kuin, E. A. C., ten Berge, I. J. M., & Bemelman, F. J. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12032 · Cited by 119
Coutermarsh‐Ott, S. L., Eden, K. B., & Allen, I. C. (2016) · Journal of General Virology · doi:10.1099/jgv.0.000401 · Cited by 119
Yun, H., Xie, F., Delzell, E., et al. (2014) · Arthritis Care & Research · doi:10.1002/acr.22470 · Cited by 118
Dumas, G., Habibi, A., Onimus, T., Merle, J., Razazi, K., Dessap, A. M., Galactéros, F., Michel, M., Frémeaux‐Bacchi, V., Pirenne, F., et al. (2016) · Blood · doi:10.1182/blood-2015-09-669770 · Cited by 117
Hoffman, H. M., Throne, M. L., Amar, N. J., Cartwright, R. C., Kivitz, A., Soo, Y., & Weinstein, S. P. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.09.009 · Cited by 115
Cruz, A. A., Lima, F., Sarinho, E., Ayre, G., Martin, C., Fox, H., & Cooper, P. J. (2007) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2007.02650.x · Cited by 111
Bykerk, V., Östör, A., Álvaro-Gracia, J., Pavelka, K., Ivorra, J., Graninger, W., Bensen, W., Nurmohamed, M., Krause, A., Bernasconi, C., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201087 · Cited by 107
Liu, Y., Zhang, S., Li, D., & Jiang, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059872 · Cited by 106
Helley, D., de Latour, R. P., Porcher, R., Rodrigues, C. A., Galy–Fauroux, I., Matheron, J., Duval, A., Schved, J., Fischer, A., Socié, G., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.016121 · Cited by 102
Yun, H., Xie, F., Delzell, E., Chen, L., Levitan, E. B., Lewis, J. D., Saag, K. G., Beukelman, T., Winthrop, K. L., Baddley, J. W., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204011 · Cited by 101
Self-citationWeinblatt, M. E., Mease, P., Mysler, E., Takeuchi, T., Drescher, E., Berman, A., Xing, J., Zilberstein, M., Banerjee, S., & Emery, P. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39249 · Cited by 98
Barone, M., Notarnicola, A., Lopalco, G., Viggiani, M. T., Sebastiani, F., Covelli, M., Iannone, F., Avolio, A. W., Leo, A. D., Cantarini, L., et al. (2015) · Hepatology · doi:10.1002/hep.27716 · Cited by 97
El‐Qutob, D. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8490-y · Cited by 96
Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease
Bilginer, Y., Ayaz, N. A., & Özen, S. (2009) · Clinical Rheumatology · doi:10.1007/s10067-009-1279-8 · Cited by 95
Kammuller, M. E., Tsai, T., Griffiths, C. E. M., Kapoor, N., Kolattukudy, P. E., Brees, D., Chibout, S., Safi, J., & Fox, T. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.34 · Cited by 94
Burrage, M., Robinson, A., Borrow, R., et al. (2002) · Infection and Immunity · doi:10.1128/iai.70.9.4946-4954.2002 · Cited by 91
Vitale, A., Insalaco, A., Sfriso, P., Lopalco, G., Emmi, G., Cattalini, M., Manna, R., Cimaz, R., Priori, R., Talarico, R., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00380 · Cited by 91
Asif, A., Nayer, A., & Haas, C. S. (2016) · Journal of Nephrology · doi:10.1007/s40620-016-0357-7 · Cited by 90
Cantarini, L., Lopalco, G., Caso, F., Costa, L., Iannone, F., Lapadula, G., Anelli, M. G., Franceschini, R., Menicacci, C., Galeazzi, M., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.08.008 · Cited by 89
Omalizumab-induced decrease of FcɛRI expression in patients with severe allergic asthma
Chanez, P., Contin‐Bordes, C., Garcia, G., Verkindre, C., Didier, A. P., Frederic de, B. L. A. Y., de Lara, M. T., Blanco, P., Moreau, J., Robinson, P., et al. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.07.011 · Cited by 88
The Inflammasome and IL-1β: Implications for the Treatment of Inflammatory Diseases
Satoh, T. K., Otsuka, A., Contassot, E., & French, L. E. (2015) · Immunotherapy · doi:10.2217/imt.14.106 · Cited by 83
Santolaya, M. E., O’Ryan, M., Valenzuela, M. T., et al. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25505 · Cited by 82
Treatment of Acute Gouty Arthritis in Complex Hospitalized Patients With Anakinra
Ghosh, P., Cho, M., Rawat, G., Simkin, P. A., & Gardner, G. C. (2013) · Arthritis Care & Research · doi:10.1002/acr.21989 · Cited by 80
Cooper, P. J., Ayre, G., Martín, C., Rizzo, J. Â., Ponte, E. V., & Cruz, Á. A. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01601.x · Cited by 78
Weitz, I. C., Razavi, P., Rochanda, L., Zwicker, J. I., Furie, B., Manly, D. A., Mackman, N., Green, R., & Liebman, H. A. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.04.001 · Cited by 77
Nakamura, J., Nagashima, T., Nagatani, K., et al. (2014) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12359 · Cited by 77
Bohl, S., Kuchenbauer, F. C., von Harsdorf, S., Klövekorn, N., Schönsteiner, S. S., ROUHI, A. M., Schwarzwälder, P., Döhner, H., Bunjes, D. W., & Bommer, M. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.08.019 · Cited by 77
Sundy, J. S., Schumacher, H. R., Kivitz, A., Weinstein, S. P., Wu, R., King-Davis, S., & Evans, R. R. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.131226 · Cited by 75
Altman, M. C., Lenington, J., Bronson, S., & Ayars, A. G. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.01.013 · Cited by 75
Ottaviani, S., Brunier, L., Sibilia, J., Maurier, F., Ardizzone, M., Wendling, D., Gill, G., Palazzo, É., Meyer, O., & Dieudé, P. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.07.018 · Cited by 74
Fernández‐Ruiz, M., Meije, Y., Manuel, O., Akan, H., Carratalà, J., Aguado, J. M., & Delaloye, J. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.029 · Cited by 74
Self-citationPlatonov, A. E. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00440-7 · Cited by 73
IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies
Blauvelt, A., Lebwohl, M., & Bissonnette, R. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.144 · Cited by 73
Effectiveness and Safety of Anakinra for Management of Refractory Pericarditis
Jain, S., Thongprayoon, C., Espinosa, R. E., Hayes, S. N., Klarich, K. W., Cooper, L. T., Moder, K. G., Anavekar, N. S., Oh, J. K., & Matteson, E. L. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.07.047 · Cited by 72
Efficacy and safety of biological agents in adult-onset Still’s disease
Cavalli, G., Franchini, S., Aiello, P., Guglielmi, B., Berti, A., Campochiaro, C., Sabbadini, M. G., Baldissera, E. M., & Dagna, L. (2015) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2014.992949 · Cited by 72
The biology behind interleukin-6 targeted interventions
Liu, X., Jones, G. W., Choy, E., & Jones, S. A. (2016) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000255 · Cited by 71
Guler, R., Parihar, S. P., Spohn, G., Johansen, P., Brombacher, F., & Bachmann, M. F. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.10.045 · Cited by 70
Complement and fungal pathogens: an update
Speth, C., Rambach, G., Würzner, R., & Lass‐Flörl, C. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01597.x · Cited by 69
Against all odds: anti-IgE for intrinsic asthma?
Lommatzsch, M., Korn, S., Buhl, R., & Virchow, J. C., Jr. (2013) · Thorax · doi:10.1136/thoraxjnl-2013-203738 · Cited by 69
Burbach, M., Suberbielle, C., Brochériou, I., Ridel, C., Mesnard, L., Dahan, K., Rondeau, É., & Hertig, A. (2014) · Transplantation · doi:10.1097/tp.0000000000000184 · Cited by 68
Wang, F., Liu, T., Zhu, L., Li, S., & Mao, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166833 · Cited by 68
Vasu, S., Wu, H. M., Satoskar, A. A., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.87 · Cited by 67
Motsinger‐Reif, A. A., Antas, P. R. Z., Oki, N. O., Levy, S., Holland, S. M., & Sterling, T. R. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-37 · Cited by 66
Human Helminths and Allergic Disease: The Hygiene Hypothesis and Beyond
Santiago, H. C., & Nutman, T. B. (2016) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.16-0348 · Cited by 66
Wójtowicz, A., Gresnigt, M. S., Lecompte, T., Bibert, S., Manuel, O., Joosten, L. A. B., Rüeger, S., Berger, C., Boggian, K., Cusini, A., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu636 · Cited by 65
The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions
Adelzadeh, L., Jourabchi, N., & Wu, J. J. (2013) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12307 · Cited by 63
Takeuchi, T., Tanaka, Y., Yamanaka, H., Amano, K., Nagamine, R., Park, W., Shiozawa, K., Tsukano, M., Wei, J. C., Shao, J., et al. (2015) · Modern Rheumatology · doi:10.3109/14397595.2015.1074648 · Cited by 61
den Broeder, A. A., de Jong, E., Franssen, M. J. A. M., Jeurissen, M. E. C., Flendrie, M., & van den Hoogen, F. H. J. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.033662 · Cited by 61
The Changing Epidemiology of Meningococcal Disease
Cohn, A. C., & MacNeil, J. R. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.08.002 · Cited by 59
Applying complement therapeutics to rare diseases
Reis, E. S., Mastellos, D. C., Yancopoulou, D., Risitano, A. M., Ricklin, D., & Lambris, J. D. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.08.009 · Cited by 58
Menzella, F., Lusuardi, M., Galeone, C., Taddei, S., & Zucchi, L. (2015) · Journal of Asthma and Allergy · doi:10.2147/jaa.s40244 · Cited by 58
Settas, L., Tsimirikas, G., Vosvotekas, G., Triantafyllidou, E., & Nicolaides, P. (2007) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31812e00a1 · Cited by 57
Ling, Y., & Puel, A. (2014) · Actas Dermo-Sifiliográficas · doi:10.1016/s0001-7310(14)70016-x · Cited by 57
Volokhina, E. B., van de Kar, N. C. A. J., Bergseth, G., van der Velden, T. J. A. M., Westra, D., Wetzels, J. F. M., van den Heuvel, L. P., & Mollnes, T. E. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.05.018 · Cited by 55
Papp, K. A., Bachelez, H., Blauvelt, A., Winthrop, K. L., Romiti, R., Ohtsuki, M., Acharya, N. V., Braun, D. K., Mallbris, L., Zhao, F., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15723 · Cited by 53
Self-citationFrazer‐Abel, A. A., Sepiashvili, L., Mbughuni, M. M., & Willrich, M. A. V. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.06.001 · Cited by 48
Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B
Nagashima, T., & Minota, S. (2008) · Lara D. Veeken · doi:10.1093/rheumatology/ken384 · Cited by 46
Chioato, A., Noseda, E., Felix, S., Stevens, M., Giudice, G. D., Fitoussi, S., & Kleinschmidt, A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00175-10 · Cited by 43
Attia, A., Abushouk, A. I., Ahmed, H., Gadelkarim, M., Elgebaly, A. S., Hassan, Z., Abdel‐Daim, M. M., & Negida, A. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0500-9 · Cited by 43
Iking-Konert, C., von Hinüber, U., Richter, C., Schwenke, H., Gürtler, I., Kästner, P., Klapperich, B., Peters, M., & Burmester, G. (2016) · Rheumatology · doi:10.1093/rheumatology/kev372 · Cited by 42
Not all monoclonals are created equal – Lessons from failed drug trials in Crohn's disease
Kaser, A. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.04.005 · Cited by 40
Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
Shimoda, T., Odajima, H., Okamasa, A., Kawase, M., Komatsubara, M., Mayer, B., Yancey, S. W., & Ortega, H. G. (2017) · Allergology International · doi:10.1016/j.alit.2016.11.006 · Cited by 39
Complement inhibition as potential new therapy for antibody-mediated rejection
Eskandary, F. A., Wahrmann, M., Mühlbacher, J., & Böhmig, G. A. (2015) · Transplant International · doi:10.1111/tri.12706 · Cited by 33
Ishiguro, N., Atsumi, T., Harigai, M., Mimori, T., Nishimoto, N., Sumida, T., Takeuchi, T., Tanaka, Y., Nakasone, A., Takagi, N., et al. (2016) · Modern Rheumatology · doi:10.1080/14397595.2016.1206507 · Cited by 32
Eculizumab use in kidney transplantation
Johnson, C. K., & Leca, N. (2015) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000249 · Cited by 31
Brodalumab for the treatment of psoriasis
Galluzzo, M., D’Adamio, S., Bianchi, L., & Talamonti, M. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1246957 · Cited by 31
Omalizumab for the treatment of chronic urticaria
Zuberbier, T., & Maurer, M. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.993971 · Cited by 30
Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma
Lim, H. F., & Nair, P. K. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2015.1000867 · Cited by 29
Cited by
Eosinophil responses during COVID-19 infections and coronavirus vaccination
Lindsley, A. W., Schwartz, J. T., & Rothenberg, M. E. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.021 · Cited by 354
The Diagnosis and Treatment of Tuberculosis
Suárez, I., Fünger, S. M., Kröger, S., Rademacher, J., Fätkenheuer, G., & Rybniker, J. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0729 · Cited by 264
Metadata
- Authors
- Winthrop, K. L., Mariette, X., Silva, J. T., Benamu, E., Calabrese, L. H., Dumusc, A., Smolen, J. S., Aguado, J. M., & Fernández-Ruiz, M.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 24
- Pages
- S21-S40
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W2785674074
- Cited by
- 259
- References
- 214
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.